AbCellera arrived at its second-quarter report as a company in the middle of a transition with two contradictory clocks running. For years the Vancouver-based antibody discoverer earned its keep by selling its AI-driven platform to pharma partners, collecting research fees plus small royalty stakes if a partner's drug ever reached market. That model built a large cash pile but left the company almost entirely dependent on other people's drug-development success. This period, the clock on its own ability to be a drug company struck for the first time. On August 10, AbCellera announced positive top-line Phase 2 data for ABCL635, its lead internally-developed antibody for moderate-to-severe menopausal hot flashes: the study met its primary endpoints, cutting both hot-flash frequency and severity versus placebo after a single subcutaneous dose, with supportive sleep and patient-impression signals and a clean tolerability profile. In a single readout, a first-in-class GPCR-targeting antibody - the type of target the antibody field historically dismissed as undruggable - demonstrated efficacy in patients.
The second clock is less flattering. The partner-discovery engine that pays the bills is thinning. Revenue fell to $4.1 million in the quarter, down 76% from a year earlier, almost entirely because the year-ago period carried a large one-time licensing recognition that did not repeat; the count of partner-led programs in which AbCellera holds a downstream stake shrank to 35 from 44 at the end of 2025. The offset came from the balance sheet and the deal desk: two new collaborations with Jazz and Vertex added over $100 million in combined upfront cash, and AbCellera ended the quarter with $540 million in cash and marketable securities against roughly $896 million of shareholders' equity, on top of more than $110 million in available non-dilutive government funding.
What changed is that the company now has two ways to win. The ABCL635 readout validates that AbCellera can discover and develop its own medicines, not just rent out the finder's talent; the Jazz and Vertex deals show the legacy platform business can still attract blue-chip partners willing to pay upfront. What decides the thesis is whether a single small, short Phase 2 study converts into a large Phase 3 program and, eventually, a commercial asset - and whether the partner book stops contracting. The stock, which tripled off its 52-week low into the high-single digits on the readout, is pricing the first clock and largely ignoring the second.